These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25727587)

  • 1. Periocular skin hyperpigmentation in children treated with prostaglandin analogues.
    Al-Zobidi M; Khandekar R; Craven ER; Hanafi S; Edward DP
    J AAPOS; 2015 Feb; 19(1):49-53. PubMed ID: 25727587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs.
    Duman N; Duman R; Yavaş GF; Doğruk Kaçar S; Özuğuz P; Çetinkaya E
    Cutan Ocul Toxicol; 2017 Mar; 36(1):9-11. PubMed ID: 26911512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin-Associated Periorbitopathy in Children and Young Adults with Glaucoma.
    Kim JS; Blizzard S; Woodward JA; Leyngold IM; Liss J; Freedman SF
    Ophthalmol Glaucoma; 2020; 3(4):288-294. PubMed ID: 33008561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unilateral Prostaglandin-Associated Periorbitopathy: A Syndrome Involving Upper Eyelid Retraction Distinguishable From the Aging Sunken Eyelid.
    Rabinowitz MP; Katz LJ; Moster MR; Myers JS; Pro MJ; Spaeth GL; Sharma P; Stefanyszyn MA
    Ophthalmic Plast Reconstr Surg; 2015; 31(5):373-8. PubMed ID: 25393907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction.
    Mocan MC; Uzunosmanoglu E; Kocabeyoglu S; Karakaya J; Irkec M
    J Glaucoma; 2016 Sep; 25(9):770-4. PubMed ID: 27513901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.
    Yoshino T; Fukuchi T; Togano T; Seki M; Ikegaki H; Abe H
    Jpn J Ophthalmol; 2013 Mar; 57(2):172-8. PubMed ID: 23208023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latisse-induced periocular skin hyperpigmentation.
    Priluck JC; Fu S
    Arch Ophthalmol; 2010 Jun; 128(6):792-3. PubMed ID: 20547960
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
    Chou SY; Chou CK; Kuang TM; Hsu WM
    Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretarsal skin height changes in children receiving topical prostaglandin analogue therapy for primary congenital glaucoma.
    Al-Zobidi M; Khandekar R; Cruz A; Craven RE; Souru C; Malik R; Edward DP
    J AAPOS; 2018 Aug; 22(4):290-293.e1. PubMed ID: 29792934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periocular changes in topical bimatoprost and latanoprost use.
    Karslioğlu MZ; Hoşal MB; Tekeli O
    Turk J Med Sci; 2015; 45(4):925-30. PubMed ID: 26422869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
    Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
    Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of latanoprost-induced diffuse facial skin hyperpigmentation.
    Kim HY; Lee SK; Lee JH; Suh JH; Kim MS; Lee UH
    J Cosmet Dermatol; 2019 Dec; 18(6):1717-1720. PubMed ID: 30924263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Side-effects and risk profile of latanoprost 0.005% (Xalatan)].
    Schlote T
    Ophthalmologe; 2002 Sep; 99(9):724-9. PubMed ID: 12219263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
    Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
    Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy.
    N Horváth O; Letulé V; Ruzicka T; Herzinger T; Goldscheider I; von Braunmühl T
    J Cosmet Dermatol; 2017 Mar; 16(1):18-20. PubMed ID: 27595988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma.
    Sakata R; Fujishiro T; Saito H; Nakamura N; Honjo M; Shirato S; Miyamoto E; Yamada Y; Aihara M
    J Ocul Pharmacol Ther; 2023; 39(1):63-69. PubMed ID: 36318495
    [No Abstract]   [Full Text] [Related]  

  • 17. Latanoprost and periocular skin color changes.
    Wand M; Ritch R; Isbey EK; Zimmerman TJ
    Arch Ophthalmol; 2001 Apr; 119(4):614-5. PubMed ID: 11296032
    [No Abstract]   [Full Text] [Related]  

  • 18. Observations on Prostaglandin Orbitopathy.
    Custer PL; Kent TL
    Ophthalmic Plast Reconstr Surg; 2016; 32(2):102-5. PubMed ID: 25719374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin Eyedrops Are Associated With Decreased Thicknesses of Eyelid Dermis and Orbicularis Oculi Muscle: Ultrasonographic Findings.
    Goh AS; Nassiri N; Kohn JC; Rootman DB; Giaconi J; Law SK; Coleman AL; Caprioli J; Goldberg RA
    Ophthalmic Plast Reconstr Surg; 2016; 32(5):337-41. PubMed ID: 26237530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study.
    Guo Y; Ha JY; Piao HL; Sung MS; Park SW
    BMC Ophthalmol; 2020 Jul; 20(1):277. PubMed ID: 32650746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.